Soligenix Finalizes Prospectus for $2.96M ATM Expansion, Totaling $6.4M Amidst Going Concern
SNGX has more than doubled off its 52-week low of $0.28 on elevated volume (3.2× avg).
Summary
Soligenix filed a prospectus supplement to enable the sale of an additional $2.956 million in common stock via its ATM program, increasing the total program to $6.401 million, a move essential for its liquidity given recent operational setbacks and a going concern warning.
Key Events · Financing and Capital Events · SNGX
-
ATM Program Expansion Finalized
This prospectus supplement enables the sale of an additional $2.956 million in common stock through the existing At-The-Market (ATM) offering, formalizing the capacity increase announced in a concurrent 8-K filing.
-
Total ATM Capacity Reaches $6.4 Million
This expansion increases the total potential capital raise under the ATM program to $6.401 million, combining the original $3.45 million with the new capacity.
-
Significant Potential Dilution
The new capacity alone represents over 20% of the current market capitalization, with the total program representing over 44%, indicating substantial potential dilution for existing shareholders.
-
Urgent Capital Need
The company is utilizing its full S-3 eligibility under the one-third public float rule, highlighting an urgent need for capital following a going concern warning and the recent halt of its pivotal Phase 3 clinical trial.
Analysis · SNGX · Life Sciences
This prospectus supplement formalizes the company's ability to sell up to an additional $2.956 million in common stock through its At-The-Market (ATM) program, bringing the total program capacity to $6.401 million. This significant capital raise, representing a substantial portion of the company's market capitalization, is critical for Soligenix's operations, especially following a going concern warning and the recent futility halt of its pivotal Phase 3 clinical trial. The company is maximizing its S-3 eligibility to raise capital, indicating an urgent need for funds.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 41.9% of the 327 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.46%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, SNGX was trading at $0.89 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $14.4M. The 52-week trading range was $0.28 to $6.23. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.